Included in the formulation
АТХ:A.03.A Drugs used for bowel disorders
Pharmacodynamics:It blocks m-holinoretseptory parasympathetic nervous system.
Has spasmolytic effect: relaxes the smooth muscles of the bronchi, gastrointestinal and urinary systems.
Pharmacokinetics:Does not have a central action.
Indications:Applicable with the purpose of premedication before the operation to reduce the secretion of bronchial and salivary glands, with peptic ulcer of the stomach and duodenum, hepatic and renal colic, spasms of the musculature of the internal organs.
XI.K20-K31.K26 Duodenal ulcer
XI.K20-K31.K25 Stomach ulcer
XI.K20-K31.K29 Gastritis and duodenitis
XI.K80-K87.K80 Gallstone disease [cholelithiasis]
XIV.N20-N23.N23 Renal colic, unspecified
XXI.Z40-Z54.Z51.4 Preparatory procedures for subsequent treatment, not elsewhere classified
Contraindications:Hypertrophy of the prostate, renal and hepatic insufficiency, disorders of urination, keratotonus, iris synechia, closed-angle and open-angle glaucoma.
Individual intolerance.
Carefully:Cardiovascular diseases with a tendency to atrial fibrillation (IHD, arterial hypertension, stenosis of the mitral valve).
Reflux esophagitis, achalasia of the esophagus, intestinal atony.
Children's cerebral palsy, Down's disease.
Lactation period.
Pregnancy and lactation:Recommendations for FDA - Category B. It is used according to the indications.
Dosing and Administration:Inside before meals, 2-4 mg 2-3 times / day.
Intravenous, intramuscular, subcutaneous: 0.5-1 mg 2-3 times / day.
The highest daily dose: 15 mg for oral administration, 6 mg for parenteral administration.
The highest single dose: 5 mg for oral administration, 2 mg for parenteral administration.
Side effects:Dizziness, dry mouth, tachycardia, urinary retention, constipation, photophobia, mydriasis, paralysis of accommodation, impaired tactile perception.
Allergic reactions.
Overdose:Symtomas: impaired vision, unsteadiness of gait, difficulty breathing, drowsiness, hallucinations, hyperthermia, muscle weakness.
Treatment: introduction of physostigmine: intravenously from 0.5 to 2 mg at a speed of up to 1 mg / min, not more than 5 mg / day or neostigmine methylsulfate intramuscularly 1 mg every 2-3 hours, intravenously - up to 2 mg.
Interaction:Simultaneous use with phenylephrine can cause the development of hypertension.
Procainamide potentiates the action of methocinium iodide.
Special instructions:Monitoring of liver function, intraocular pressure. It is not recommended to use the drug for hyperthermia, since when suppressing the secretion of sweat glands, body temperature can increase.